This week– J&J’s outlook for coronavirus vaccines, Cosentyx comes in strong for Novartis, Biogen’s views on Aduhelm pricing, competition in the “dustat” sector, and dealing with endemic COVID-19.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
